September 21, 2012
The Swedish pharmaceutical company Medivir AB announced a phase IIa combination trial of simeprevir (TMC435), a protease inhibitor, and TMC647055, a non-nucleoside inhibitor for treatment of chronic hepatitis C. At present, Simeprevir is in phase II clinical development and is being developed jointly by Medivir and Janssen Research & Development (R&D), Ireland. The non-nucleoside inhibitor TMC647055 is also developed by Janssen R&D. The trial will be an open label study of chronically- infected hepatitis C patients with HCV genotype-1a or 1b to determine the efficacy, safety, and tolerability of the combined drugs. The endpoint of the study is the patients' sustained virologic response 12 weeks after end of treatment (SVR12), that is the number of patients who will be virus free 12 weeks after the end of the combination drug treatment. Simeprevir, TMC647055, and low-dose ritonavir will be co-administered once daily with and without ribavirin for 12 weeks. The second part of the trial will test the same regimen in prior null responder patients chronically infected with HCV genotype 1a. For information about the study see www.clinicaltrials.gov.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|